Table 1.
Demographic and clinical characteristics of patient cohort
| Variable | All patients (n = 599) | Wild type (n = 151) | BRAFV600E (n = 260) | p value* |
|---|---|---|---|---|
| Age in years (SD) | 45.0 (14.5) | 43.4 (14.5) | 45.8 (14.7) | 0.14 |
| Female, n (%) | 462 (76.8) | 121 (80.1) | 194 (74.6) | 0.20 |
| Tumor size in mm (SD) | 17.9 (12.2) | 20.0 (13.9) | 17.6 (12.0) | 0.12 |
| Multifocal, n (%) | 294 (49.0) | 72 (48.0) | 123 (47.3) | 0.89 |
| Family Hx PTC, n (%) | 28 (4.7) | 7 (4.6) | 16 (6.1) | 0.52 |
| Follow-up (years), median (IQR) | 10.3 (5.4–12.2) | 10.6 (6.2–13.1) | 9.7 (3.9–11.2) | 0.09 |
| Lymph node metastases | 198 (33.1) | 45 (29.8) | 97 (37.3) | 0.12 |
| Lymphovascular invasion, n (%) | 36 (6.0) | 13 (8.7) | 18 (6.9) | 0.52 |
| Extrathyroidal extension (%) | 88 (14.6) | 15 (9.9) | 49 (18.9) | 0.02 |
| Radioactive iodine | 480 (81.5) | 124 (83.2) | 201 (79.1) | 0.32 |
| Subtype, n (%) | 0.001 | |||
| Normal risk (ref.) | 509 (85.3) | 112 (74.7) | 247 (95.0) | |
| Low risk | 79 (13.2) | 35 (23.3) | 10 (3.9) | |
| High risk | 9 (1.5) | 3 (2.0) | 3 (1.1) | |
| T stage (AJCC 8th), n (%) | 0.97 | |||
| T1 | 427 (71.1) | 104 (68.9) | 180 (69.2) | |
| T2 | 115 (19.1) | 31 (20.5) | 50 (19.2) | |
| T3 | 41 (6.8) | 13 (8.6) | 18 (6.9) | |
| T4 | 18 (3.0) | 3 (2.0) | 12 (4.6) | |
| Recurrence, n (%) | 78 (13.0) | 15 (9.9) | 48 (18.5) | 0.02 |
| Time to recurrence in years, mean (SD) | 3.0 (3.2) | 2.85 (2.62) | 3.33 (3.55) | 0.91 |
Low risk = follicular variant of papillary thyroid cancer (PTC), warthin-like, cribriform-morular variant; normal risk = classical PTC, mixed follicular variant PTC, solid, oncocytic; high risk = tall cell variant, diffuse sclerosing variant
*
Represents comparison of wild type versus BRAFV600E